Organon & Co.
DB:7XP 株式レポート
Organon マネジメント Organonの CEO はKevin Aliで、 Jun2021年に任命され、 の在任期間は 3.42年です。 の年間総報酬は$ 14.83Mで、 8.4%給与と91.6%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.056%を直接所有しており、その価値は€ 2.13M 。経営陣と取締役会の平均在任期間はそれぞれ3.4年と3.4年です。
主要情報 CEO給与比率 8.4% CEO在任期間 3.4yrs CEOの所有権 0.06% 経営陣の平均在職期間 3.4yrs 取締役会の平均在任期間 3.4yrs
経営陣の近況
Organon & Co., Annual General Meeting, Jun 04, 2024 Apr 28
Organon & Co. Announces Departure of Sandra Milligan as Head of Research and Development Effective January 5, 2024 Dec 06
Organon Announces Two Leadership Appointments Sep 06
Organon & Co. Appoints Kirke Weaver as General Counsel and Corporate Secretary, Effective January 1, 2023 Dec 13
Organon & Co. Announces Resignation of Deborah H. Telman as Executive Vice President, General Counsel and Corporate Secretary, Effective July 22, 2022 Jul 13
Organon & Co. Appoints Meghan Rivera as US Managing Director, Organon Mar 03
すべての更新を表示
Organon & Co. Updates on FDA Review of VTAMA (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older Nov 05
Third quarter dividend of US$0.28 announced Nov 02 Organon & Co. Revises Earnings Guidance for the Full Year 2024
New major risk - Revenue and earnings growth Nov 01
Third quarter 2024 earnings released: EPS: US$1.39 (vs US$0.23 in 3Q 2023) Nov 01
Organon & Co. (NYSE:OGN) completed the acquisition of Dermavant Sciences Ltd. from Roivant Sciences Ltd. (NasdaqGS:ROIV) and others. Oct 28
Organon & Co. to Report Q3, 2024 Results on Oct 31, 2024 Oct 09
Shanghai Henlius Biotech, Inc. and Organon Announces Phase 3 Comparative Clinical Study of Perjeta®? (pertuzumab) Biosimilar Candidate HLX11 Oct 01 Organon & Co. (NYSE:OGN) agreed to acquire Dermavant Sciences Ltd. from Roivant Sciences Ltd. (NasdaqGS:ROIV) and others for approximately $1.2 billion. Sep 18
Second quarter dividend of US$0.28 announced Aug 08
Second quarter 2024 earnings released: EPS: US$0.76 (vs US$0.95 in 2Q 2023) Aug 07 Organon & Co. Affirms Revenue Guidance for the Full Year 2024
Investor sentiment deteriorates as stock falls 16% Aug 06
Organon & Co. to Report Q2, 2024 Results on Aug 06, 2024 Jul 10
Shanghai Henlius Biotech, Inc. and Organon Announces That the European Medicines Agency Has Validated the Marketing Authorization Applications (Maas) for Hlx14 May 25
First quarter dividend of US$0.28 announced May 05
First quarter 2024 earnings released: EPS: US$0.79 (vs US$0.70 in 1Q 2023) May 03 Organon & Co. Provides Earnings Guidance for the Year 2023
Organon & Co., Annual General Meeting, Jun 04, 2024 Apr 28
Organon & Co. to Report Q1, 2024 Results on May 02, 2024 Apr 09 US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary
Fourth quarter dividend of US$0.28 announced Feb 18
Full year 2023 earnings released: EPS: US$4.01 (vs US$3.61 in FY 2022) Feb 16 Organon & Co. Declares Quarterly Dividend, Payable on March 14, 2024
Organon & Co. to Report Q4, 2023 Results on Feb 15, 2024 Feb 02
Investor sentiment improves as stock rises 25% Jan 11
Organon’S Xaciato (Clindamycin Phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis in Females Aged 12 and Older Jan 10
Organon & Co. Announces Departure of Sandra Milligan as Head of Research and Development Effective January 5, 2024 Dec 06
Investor sentiment deteriorates as stock falls 16% Nov 11
Samsung Bioepis & Organon Announces FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (Adalimumab-bwwd) Nov 08
Organon & Co. Declares a Quarterly Dividend, Payable on December 14, 2023 Nov 03
Third quarter 2023 earnings released: EPS: US$0.23 (vs US$0.89 in 3Q 2022) Nov 03
Organon & Co. to Report Q3, 2023 Results on Nov 02, 2023 Oct 20
Organon & Co.(NYSE:OGN) dropped from FTSE All-World Index (USD) Sep 18
Organon Announces First Real-World Observational Study of the JADA® System Sep 15
Organon Announces Two Leadership Appointments Sep 06
Organon & Co. Revises Earnings Guidance for the Full Year 2023 Aug 10
Second quarter 2023 earnings released: EPS: US$0.95 (vs US$0.92 in 2Q 2022) Aug 09
Samsung Bioepis & Organon Announces Topline Results from Interchangeability Study of SB5 Humira Biosimilar Aug 02
Organon & Co. to Report Q2, 2023 Results on Aug 08, 2023 Jul 18
Organon & Co. & Samsungbioepis Co,.Ltd Announces US Launch of Humira Biosimilar Hadlima (adalimumab-Bwwd) in Multiple Presentations Consistent with Originator Jul 03 Organon & Co. Declares Guidance Quarterly Dividend, Payable on June 15, 2023
First quarter 2023 earnings released: EPS: US$0.70 (vs US$1.37 in 1Q 2022) May 05
Full year 2022 earnings released: EPS: US$3.61 (vs US$5.33 in FY 2021) Feb 17 Organon Declares Quarterly Dividend, Payable on March 16, 2023
Organon & Co. to Report Q4, 2022 Results on Feb 16, 2023 Feb 07
Organon & Co. Appoints Kirke Weaver as General Counsel and Corporate Secretary, Effective January 1, 2023 Dec 13
Organon Canada Launches Ontruzant®, A Biosimilar of the Reference Biologic Herceptin®, Providing Patients in Canada with Certain Breast and Gastric Cancers with an Additional Therapeutic Option At A Lower Cost Nov 15
Organon Canada Launches Aybintio Providing New Option at Reduced Cost for Canadians Living with Certain Aggressive Forms of Cancer Nov 08
Third quarter 2022 earnings released: EPS: US$0.89 (vs US$1.27 in 3Q 2021) Nov 04 Organon & Co. Revises Earnings Guidance for the Full Year 2022
Organon & Co. to Report Q3, 2022 Results on Nov 03, 2022 Oct 21
Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration Humira® Biosimilar Hadlima™ Aug 18
Second quarter 2022 earnings released: EPS: US$0.92 (vs US$1.70 in 2Q 2021) Aug 05 Organon & Co. Declares Quarterly Dividend, Payable on September 15, 2022
Organon & Co. to Report Q2, 2022 Results on Aug 04, 2022 Jul 22
Organon & Co. Announces Resignation of Deborah H. Telman as Executive Vice President, General Counsel and Corporate Secretary, Effective July 22, 2022 Jul 13
First quarter 2022 earnings released: EPS: US$1.37 (vs US$1.56 in 1Q 2021) May 06
Organon & Co. Declares Quarterly Dividend, Payable on June 16, 2022 May 06
Organon & Co. to Report Q1, 2022 Results on May 05, 2022 Apr 22
Organon & Co. Appoints Meghan Rivera as US Managing Director, Organon Mar 03
Investor sentiment improved over the past week Feb 28
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 18 Organon & Co. Provides Earnings Guidance for Full Year 2022
Organon & Co. to Report Q4, 2021 Results on Feb 17, 2022 Feb 02
Samsung Bioepis Co., Ltd. and Organon & Co. announce the U.S. Food and Drug Administration accept for review the supplemental Biologics License Application Jan 06
Organon & Co. (NYSE:OGN) completed the acquisition of Forendo Pharma Ltd from Karolinska Development AB (publ) (OM:KDEV), KD Co-Investment Fund KB, fund managed by Karolinska Development AB (publ) and others. Dec 14
Independent Director recently bought €87k worth of stock Aug 20
Organon & Co. Declares Inaugural Quarterly Dividend, Payable on September 13, 2021 Aug 13
Investor sentiment improved over the past week Aug 12 Organon & Co.(NYSE:OGN) dropped from Russell Top 50 Index
CEO報酬分析 Organon の収益と比較して、Kevin Ali の報酬はどのように変化したか？ 日付 総報酬 給与 会社業績 Sep 30 2024 n/a n/a US$1b
Jun 30 2024 n/a n/a US$1b
Mar 31 2024 n/a n/a US$1b
Dec 31 2023 US$15m US$1m US$1b
Sep 30 2023 n/a n/a US$585m
Jun 30 2023 n/a n/a US$754m
Mar 31 2023 n/a n/a US$746m
Dec 31 2022 US$14m US$1m US$917m
Sep 30 2022 n/a n/a US$1b
Jun 30 2022 n/a n/a US$1b
Mar 31 2022 n/a n/a US$1b
Dec 31 2021 US$19m US$1m US$1b
報酬と市場: Kevinの 総報酬 ($USD 14.83M ) は、 German市場 ($USD 1.97M ) の同規模の企業の平均を上回っています。
報酬と収益: Kevinの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者 Mr. Kevin Ali is Chief Executive Officer and Director of Organon & Co. since June 2, 2021. Mr. Ali served as the President of Global Enterprise Portfolio Strategy at Merck & Co., Inc. from 2019 to 2021 and ... Show more
リーダーシップ・チーム 名称 ポジション 在職期間 報酬 所有権 CEO & Director 3.4yrs US$14.83m 0.056% € 2.1m Executive VP & CFO 3.4yrs US$5.21m 0.036% € 1.3m Executive VP 1.8yrs US$3.19m 0.011% € 427.9k Executive VP & Chief Commercial Officer 3.8yrs US$3.84m 0.021% € 779.5k Executive VP and Head of Manufacturing & Supply 3.4yrs US$3.74m 0.017% € 629.4k Executive VP & Chief Information Officer 3.4yrs データなし 0.019% € 736.7k Head of Investor Relations 3.8yrs データなし データなし Chief Ethics & Compliance Officer no data データなし データなし Chief Communications Officer no data データなし データなし Executive Vice President of Corporate Development no data データなし 0.0075% € 284.3k Executive VP & Chief Human Resources Officer 3.4yrs データなし 0.013% € 479.3k Executive VP & Head of Global Business Services 3.4yrs データなし 0.0096% € 363.3k
もっと見る
経験豊富な経営陣: 7XPの経営陣は 経験豊富 であると考えられます ( 3.4年の平均在職年数)。
取締役 名称 ポジション 在職期間 報酬 所有権 CEO & Director 3.4yrs US$14.83m 0.056% € 2.1m Independent Chairman of the Board 3.4yrs US$450.00k データなし Independent Director 3.4yrs US$335.00k データなし Independent Director 3.4yrs US$320.00k 0.00025% € 9.5k Independent Director 3.4yrs US$320.00k データなし Independent Director 3.4yrs US$330.00k データなし Independent Director 3.4yrs US$320.00k データなし Independent Director 3.4yrs US$345.00k 0% € 0 Independent Director 3.4yrs US$320.00k データなし Independent Director 3.4yrs US$330.00k データなし Independent Director 3.4yrs US$320.00k 0% € 0 Independent Director 3.4yrs US$330.00k 0% € 0
もっと見る
経験豊富なボード: 7XPの 取締役会 は 経験豊富 であると考えられます ( 3.4年の平均在任期間)。
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}